Development of Inhalable Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Microparticulate System for Antituberculosis Drug Delivery

Tuberculosis (TB) is an infectious disease which affects millions of people worldwide. Inhalable polymeric dry powders are promising alternatives as anti-TB drug carriers to the alveoli milieu and infected macrophages, with potential to significantly improve the therapeutics efficiency. Here, the de...

Full description

Saved in:
Bibliographic Details
Published inAdvanced healthcare materials Vol. 7; no. 15; p. e1800124
Main Authors Miranda, Margarida S, Rodrigues, Márcia T, Domingues, Rui M A, Costa, Rui R, Paz, Elvira, Rodríguez-Abreu, Carlos, Freitas, Paulo, Almeida, Bernardo G, Carvalho, Maria Alice, Gonçalves, Carine, Ferreira, Catarina M, Torrado, Egídio, Reis, Rui L, Pedrosa, Jorge, Gomes, Manuela E
Format Journal Article
LanguageEnglish
Published Germany 01.08.2018
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Tuberculosis (TB) is an infectious disease which affects millions of people worldwide. Inhalable polymeric dry powders are promising alternatives as anti-TB drug carriers to the alveoli milieu and infected macrophages, with potential to significantly improve the therapeutics efficiency. Here, the development of a magnetically responsive microparticulate system for pulmonary delivery of an anti-TB drug candidate (P3) is reported. Microparticles (MPs) are developed based on a cast method using calcium carbonate sacrificial templates and incorporate superparamagnetic iron oxide nanoparticles to concentrate MPs in alveoli and enable drug on demand release upon actuation of an external alternate magnetic field (AMF). The MPs are shown to be suitable for P3 delivery to the lower airways and for alveolar macrophage phagocytosis. The developed MPs reveal unique and promising features to be used as an inhalable dry powder allowing the AMF control over dosage and frequency of drug delivery anticipating improved TB treatments.
ISSN:2192-2659
DOI:10.1002/adhm.201800124